Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,187.06 +3.60 (+0.30%)

Streaming Delayed Price Updated: 1:51 PM EDT, Sep 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

2 of the Best ETFs to Buy When Inflation Is Running Hot ↗

Today 10:47 EDT

Higher inflation rates have caused investors to rethink their portfolios.

Via The Motley Fool

Topics ETFs Economy

Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? ↗

Today 9:21 EDT

Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.

Via The Motley Fool

Eli Lilly (NYSE:LLY) Offers a Breakout Setup Backed by High Growth Momentum ↗

Today 8:20 EDT

Via Chartmill

Eli Lilly Just Announced Game-Changing News ↗

Today 4:23 EDT

Something new is happening in the weight loss drug market.

Via The Motley Fool

Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution ↗

September 27, 2026

The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial.

Via The Motley Fool

Here's Where Wall Street Analysts See Eli Lilly's Share Price Going ↗

September 26, 2026

Eli Lilly's share price climb has decelerated in 2026.

Via The Motley Fool

Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become ↗

September 26, 2026

Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.

Via The Motley Fool

Topics Intellectual Property

Guess Which Group of Stocks Is Back at an All-Time High? ↗

September 26, 2026

The "Magnificent Seven" ETF finally topped the record high it set in May.

Via The Motley Fool

Topics Artificial Intelligence ETFs Electric Vehicles

MarketBeat Week in Review – 09/21 - 09/25 ↗

September 26, 2026

A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.

Via MarketBeat

Topics Artificial Intelligence Bonds Economy

Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product? ↗

September 25, 2026

The drugmaker badly needs more clinical wins.

Via The Motley Fool

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? ↗

September 25, 2026

The biotech player could eventually rival big pharma companies.

Via The Motley Fool

2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges

September 25, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

Via StockStory

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? ↗

September 24, 2026

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

Via The Motley Fool

Eli Lilly (LLY) Stock Is Up, What You Need To Know

September 24, 2026

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after The U.S. Food and Drug Administration ...

Via StockStory

Explore the top gainers and losers within the S&P500 index in today's session. ↗

September 24, 2026

Via Chartmill

XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration ↗

September 24, 2026

XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.

Via The Motley Fool

Topics ETFs

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? ↗

September 24, 2026

VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility.

Via The Motley Fool

Topics ETFs

Stanley Druckenmiller, Ken Griffin, and Cathie Wood Have at Least 1 Thing in Common: They All Own This Stock ↗

September 24, 2026

This company is a leader in a high-growth field.

Via The Motley Fool

XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks ↗

September 23, 2026

XLV's broader diversification and lower fees appeal to cost-conscious investors, while PJP's concentrated pharma bet has outperformed over the past year.

Via The Motley Fool

Topics ETFs

Could Retatrutide Be Worth $10 Billion to Eli Lilly? ↗

September 23, 2026

The company continues to dominate the weight loss market.

Via The Motley Fool

Topics Law Enforcement

Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗

September 23, 2026

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Via MarketBeat

Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up? ↗

September 23, 2026

Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.

Via MarketBeat

Topics Intellectual Property Lawsuit

Why Viking Therapeutics Stock Skyrocketed on Tuesday ↗

September 23, 2026

The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.

Via The Motley Fool

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH ↗

September 22, 2026

IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income.

Via The Motley Fool

Topics ETFs

Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems ↗

September 22, 2026

Novo Nordisk is dealing with headwinds, but was its name really one of the big problems?

Via The Motley Fool

VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? ↗

September 22, 2026

VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two.

Via The Motley Fool

Topics ETFs

Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring ↗

September 22, 2026

Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth.

Via MarketBeat

Topics Initial Public Offering

Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth? ↗

September 22, 2026

When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.

Via The Motley Fool

Topics Economy

Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall. ↗

September 22, 2026

Viking and Roche both reported positive results for their weight-loss drugs Tuesday.

Via Investor's Business Daily

2 Cash-Producing Stocks with Exciting Potential and 1 We Brush Off

September 22, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.